A Phase II multi-center, randomized, double-blind, 24-week, 3-arm, parallel group, placebo-controlled study to investigate the efficacy and safety of RO5285119 in children and adolescents age 5-17 with Autism Spectrum Disorder (ASD)
Research Grant
Administered By
Psychiatry, Child & Family Mental Health & Community Psychiatry
Awarded By
Roche Biomedical Laboratories
Start Date
April 13, 2016
End Date
October 31, 2020
Administered By
Psychiatry, Child & Family Mental Health & Community Psychiatry
Awarded By
Roche Biomedical Laboratories
Start Date
April 13, 2016
End Date
October 31, 2020